EB病毒编码的蛋白质在癌变过程中的作用

EB病毒是一种与人类肿瘤有密切关系的DNA病毒.在病毒感染的不同时期有不同病毒编码蛋白质的表达,因此研究所表达不同抗原的致瘤作用将有助于研究EB病毒的致瘤机制.本文仅就EB病毒编码蛋白LMP1、EBNA1、EBNA2、BARF0和BARF1在癌变中作用的研究进展作一综述.     

泛素-蛋白酶体途径在病毒感染中的作用

泛素-蛋白酶体途径——降解溶酶体外蛋白的主要细胞内系统,在许多细胞功能中发挥重要作用。为自身利益如病毒出芽、凋亡抑制和免疫逃避,许多病毒已经进化出了利用泛素-蛋白酶体途径的不同策略。深入理解泛素-蛋白酶体途径在病毒感染中的作用有助于揭示一些病毒病的致病机理和发现新的分子靶标以开发抗病毒药物。因此,将泛素-蛋白酶体途径在病毒感染中的作用方面的最新进展作一综述。     

Epstein—Barr病毒相关疾病的免疫治疗与疫苗发展策略

简要介绍了EB病毒的感染类型及机体对不同类型EB病毒感染的免疫反应,并对EB病毒相关疾病的免疫治疗手段和疫苗发展策略进行了评述。     

EB病毒介导人鼻咽上皮细胞永生化早期阶段的生物学观察

EB病毒转化人鼻咽上皮细胞,建立体外多阶段细胞模型有利于从细胞和分子水平对肿瘤发病机制作深入研究.我们利用与鼻咽癌密切相关的EB病毒和TPA的协同作用,观察原代人胚鼻咽上皮细胞逃避老化期后其生物学特性的变化.结果表明,EB病毒感染的人胚鼻咽上皮细胞在原代培养后期老化相关半乳糖苷酶(SA-β-Gal)表达降低,形态学上发生改变,出现转化灶样集落,群体倍增时间降低,体外培养寿命延长,表明EB病毒促使部分原代人胚鼻咽上皮细胞逃避老化期、进入永生化早期阶段.这些研究资料为进一步阐明上皮细胞永生化分子机制及建立人鼻咽上皮细胞永生化模型提供实验依据.关键词EB病毒人鼻咽上皮细胞老化期永生化     

EPSTEIN-BARR病毒血清抗体阳性健康人外周血体外培养“自发性”转化的研究

对35名Epstein-Barr病毒血清抗体阳性健康人的外周血淋巴细胞进行了体外培养,观察B淋巴细胞感染了EB病毒后所导致“自发性”转化的情况。由于在培养基中加入了免疫抑制剂环胞菌素A,使“自发性”转化的发生率由26.7％提高到74.3％,说明了在血清抗体阳性健康人的外周血液中,EB病毒感染的B淋巴细胞的数量远比既往文献报道的高。     

EB病毒诱导的胸腺恶性T细胞淋巴瘤细胞体外长期培养研究

建立含有EB病毒的T细胞淋巴瘤细胞系,为探讨EB病毒的致瘤机理,研究EB病毒在T细胞淋巴瘤发生过程中的作用提供手段.在TPA协同EB病毒诱导胸腺恶性T细胞淋巴瘤动物模型的基础上,联合应用IL-2,将诱导的肿瘤组织进行体外细胞培养,成功地分离获得一株在体外长期存活的淋巴细胞TET.T细胞亚群分类实验证实TET细胞为CD4阳性的T淋巴细胞,PCR和原位杂交可检测到EB病毒的EBERs、LMP1和BARF1,并有LMP1蛋白的表达.TET细胞的获得,有望在体外建立转化细胞系,为体外研究EB病毒的致瘤机理及防治提供理想的实验材料.     

芫花酯乙和黄芫花提出液对EB病毒早期抗原的诱导和促进EB病毒对淋巴细胞转化的研究

本研究证明,用于妊娠引产的药物芫花酯乙和黄芫花提出液,能诱导Raji细胞内EB病毒的早期抗原(EA),并能促进EB病毒对淋巴细胞的转化作用。维生素甲衍生物7901能明显地抑制这两种药物诱导EA的作用。这些特性与已知的促癌物质TPA是一致的。     

芽胞杆菌及其代谢物抑制包膜病毒感染的研究进展

包膜病毒指具有一层脂质双层膜的病毒,如流感病毒、冠状病毒等,这些包膜病毒每年在世界范围内导致许多严重的疾病,严重威胁人类健康。使用抗病毒药物是预防与治疗病毒感染的主要策略,芽胞杆菌(Bacillus)及其代谢物能够抑制多种包膜病毒的感染。本文综述了芽胞杆菌代谢的粗提物、肽、酶、胞外聚合物、小双链RNA和热灭活的枯草芽胞杆菌孢子在抗包膜病毒感染中发挥的重要作用,其机制是通过直接破坏病毒包膜、阻止膜融合、与病毒基因组RNA直接配对、催化裂解病毒RNA、激活天然免疫反应等对抗病毒,期望为包膜病毒的持续预防和治疗提供参考。     

诺如病毒感染宿主免疫应答机制及疫苗研究进展

诺如病毒是引起人类急性胃肠炎的重要食源性病原之一。由于体外复制系统和感染模型的缺乏,研究人员对其宿主保护性免疫的理解始终有限,导致控制病毒感染方面的研究也受到较大阻碍。近年来,随着病毒衣壳蛋白外源表达、替代病毒的使用、志愿者实验的开展,尤其是细胞培养模型的突破,使得体液免疫和细胞免疫的研究取得较大进展。因此,本文针对诺如病毒感染宿主的先天性免疫、体液免疫和细胞免疫应答机制等进行了综述,并对后续其在诺如病毒候选疫苗研制等领域的应用进行了展望。     

EB病毒免疫逃逸的分子机制

EB病毒(Epstein-Barr vius,EBV)是一种最广泛的对人类感染的γ疱疹病毒,与人类多种疾病尤其是恶性肿瘤有关。其致病的一个重要条件是能够在人体B细胞中长期潜伏,并且在人体免疫力低下时被激活并增殖,这表明EB病毒存在逃逸宿主细胞免疫的机制。从潜伏期EB病毒基因表达的下调、干扰抗原加工和提呈、调节细胞毒性T细胞(Cytotoxic lymphocyte,CTL)免疫应答、干扰细胞因子的作用、干扰CTL的活动及抑制宿主细胞凋亡、抑制辅助性T细胞1(Helper T cell 1,Th1)免疫应答等方面,对EB病毒免疫逃逸的分子机制作一简要综述。     

Phosphonoacetic acid: inhibition of transformation of human cord blood lymphocytes by Epstein-Barr virus.

Phosphonoacetic acid disodium salt (PAA) inhibited the transformation of human cord blood lymphocytes by Epstein-Barr virus (EBV) at concentrations of 50-100 microgram/ml. At these concentrations, PAA had no effect on the multiplication of EBV transformed human lymphoblastoid cells or on the survival of human cord blood lymphocytes. The transformation of human cord blood lymphocytes by the B95-8 strain of EBV was measured by 3H-thymidine uptake, 5 days or more after infection. The degree of inhibition of transformation was correlated with the relation between the input of EBV and the concentration of PAA in the experiment. PAA inhibited the transformation even when added 24 h after EBV infection, but had no effect when added 48 h after EBV infection. The inhibitory effect of PAA could be overcome by its removal and normal 3H-thymidine uptake was restored even after 6 days of inhibition. The specificity of the inhibitory effect on EBV induced transformation of human cord blood lymphocytes is discussed.     

Chronic viral diseases.

Until 20 years ago the only chronic viral diseases known were those considered to be confined to the nervous system. As a result of recent advances in epidemiology, molecular biology and immunology, new viral diseases have been recognized and their clinical features and pathogenesis elucidated. Chronic disease may result from infection with the hepatitis B and D viruses and whatever agent or agents cause hepatitis non-A, non-B, the herpesviruses, Epstein-Barr virus, cytomegalovirus and human T-lymphotropic virus type III. These diseases have common features, including long-term or even lifetime asymptomatic carriage, viremia, with virus free in the plasma or attached to circulating mononuclear cells, presence of virus in body secretions, irreversible tissue injury in target organs and oncogenic potential. New information on these diseases is reviewed. Other chronic diseases for which the cause is currently unknown may eventually prove to be due to viral infection. In addition, vaccines may be developed for prophylaxis of some chronic viral diseases and associated malignant diseases.     

Inhibition of DNA synthesis in varicella-zoster virus-infected cells by BV-araU.

The inhibitory effect of BV-araU on DNA synthesis in human embryonic lung cells infected with varicella-zoster virus (VZV) or herpes simplex virus type 1 (HSV-1) was compared with that of acyclovir. Cellular uptake of [3H]thymidine and its incorporation into DNA was markedly stimulated by the infection with VZV or HSV-1, suggesting that the incorporation was mainly due to viral DNA synthesis. DNA synthesis in VZV-infected cells was dose-dependently suppressed by BV-araU and acyclovir, although cellular uptake of [3H]thymidine decreased in cells treated with a high concentration of drugs for an extended time. DNA synthesis in HSV-1-infected cells was also markedly inhibited by both drugs in a dose-dependent manner, without affecting cellular uptake of [3H]thymidine. The concentration of drugs inhibiting DNA synthesis was well correlated to their in vitro anti-VZV and anti-HSV-1 activities. The inhibitory concentration of BV-araU for DNA synthesis in VZV-infected cells was one-thousandth of that of acyclovir. Our results suggest that the antiviral action of BV-araU against VZV and HSV-1 is based on the inhibition of DNA synthesis in herpesvirus-infected cells.     

Antiviral activity of a bile pigment, biliverdin, against human herpesvirus 6 (HHV-6) in vitro.

Biliverdin (BV), a bile pigment, was examined for its antiviral activity against human herpesvirus-6 (HHV-6) in vitro. BV (10 micrograms/ml) markedly inhibited HHV-6 replication in MT-4 cells when the cells were treated during a virus adsorption period. Its antiviral effect was weakened when cells were treated after adsorption. Treatment of cells with BV (40 micrograms/ml) 3 hr after virus infection had no inhibitory effect on virus replication. Virus replication was also significantly inhibited by treatment of MT-4 cells with BV (10 micrograms/ml) before infection, while the virions were not inactivated by BV (20 micrograms/ml). Bilirubin and urobilin, metabolic derivatives of BV, showed slight inhibitory effects on virus replication in the cells. On the other hand, BV had no potent inhibitory activity in the replication of herpes simplex virus-1 or human cytomegalovirus. These observations suggest that BV could interact with MT-4 cells to inhibit an early stage of HHV-6 infection in a virus-specific manner.     

A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo.

We have developed a miniviral vector, pH300, based on the human herpesviruses 1 and 4, herpes simplex virus type 1 (HSV-1), and Epstein-Barr virus (EBV), carrying EBV sequences for plasmid episomal maintenance and HSV-1 sequences for amplification and packaging in multimeric form into HSV-1 capsids in the presence of a helper virus and helper cell line. A reporter gene, the bacterial lacZ gene, which expressed beta-galactosidase, was inserted into the multiple cloning site of pH300 to make pH300-lac. The packaged pH300-lac DNA was very efficient in infecting human cells in tissue culture. The pH300-lac miniviral stock was used to infect in vitro various human cell types derived from breast cancer, lung cancer, and liver cancer. Up to 95% of cells were infected and expressed beta-galactosidase activity after exposure to viral stock at a multiplicity of infection of 3. There was essentially no apparent cytotoxicity after infection of cultured cells in vitro. To test in vivo gene delivery, human liver tumor cells preimplanted subcutaneously in nude mice and injected in situ with pH300-lac showed high efficiency of ectopic gene expression. The pH300 miniviral vector is a simple and effective gene transfer system which shows potential for gene therapy of cancer and inherited diseases.     

Effects of pure interferons on Epstein-Barr virus infection in vitro.

Pure human gamma-interferon as well as alpha-interferon inhibited induction of immunoglobulin synthesis by Epstein-Barr virus but not by pokeweed mitogen in B lymphocytes from adult but not from newborn humans. The interferons inhibited the infected B lymphocytes directly, irrespective of the Epstein-Barr virus immune status of the donor, and their inhibitory effect was synergistic.     

Beyond malaria: The inhibition of viruses by artemisinin-type compounds

Natural products represent valuable chemical scaffolds for drug development. A recent success story in this context was artemisinin, which is not only active against malaria but also to other diseases. This raised the interest of artemisinin's potential for drug repurposing. On the present review, we give an overview on artemisinin's antiviral activity. There is good in vitro and in vivo evidence for the activity of artemisinin and its derivatives against DNA viruses of the Herpesviridae and Hepadnaviridae families such as cytomegaloviruses, human herpesvirus 6, herpes simplex viruses 1 and 2, Epstein-Barr virus and Hepatitis B virus. The evidence is weaker for Polyomaviruses and papilloma viruses. Weaker or no inhibitory activity in vitro has been reported for RNA viruses such as human immunodeficiency viruses 1 and 2, hepatitis C virus, influenza virus and others. Interestingly, the artemisinin derivative artesunate did not exert cross-resistance to ganciclovir-resistant HCMV and exerted synergistic inhibition in combination with several clinically established antiviral standard drugs. The antiviral activity of first generation artemisinin derivatives (e.g. artesunate, artemether, etc.) was enhanced by novel derivatives, including dimer and trimer molecules. First results on patients indicating activity in a subset of HCMV patients. Novel developments in the field of nanotechnology and synthetic biology to bioengineer microorganisms for artemisinin production may pave the way for novel drugs to fight viral infections with artemisinin-based drugs.     

Epstein-Barr virus-encoded small RNAs (EBERs) do not modulate interferon effects in infected lymphocytes.

The recent derivation of otherwise isogenic Epstein-Barr virus (EBV) recombinants carrying or lacking the EBV small RNA (EBER) genes enabled us to test whether EBERs are similar to adenovirus VA RNAs in modulating interferon (IFN) effects on virus infection. EBER-positive and -negative EBV recombinants did not differ in their sensitivity to alpha interferon (IFN-alpha)- or IFN-gamma-mediated inhibition of lymphocyte growth transformation. In addition, EBERs did not decrease the inhibitory effects of IFN on vesicular stomatitis virus replication in EBV-transformed lymphocytes. EBER deletion also did not render EBV-transformed B lymphocytes susceptible to an IFN effect on cell proliferation or EBV replication.     

Porcine FcγRIIb mediates enhancement of porcine reproductive and respiratory syndrome virus (PRRSV) infection

Antibody-dependent enhancement (ADE) of virus infection caused by the uptake of virus-antibody complexes by FcγRs is a significant obstacle to the development of effective vaccines to control certain human and animal viral diseases. The activation FcγRs, including FcγRI and FcγRIIa have been shown to mediate ADE infection of virus. In the present paper, we showed that pocine FcγRIIb, an inhibitory FcγR, mediates ADE of PRRSV infection. Stable Marc-145 cell lines expressing poFcγRIIb (Marc-poFcγRII) were established. The relative yield of progeny virus was significantly increased in the presence of sub-neutralization anti-PRRSV antibody. The Fab fragment and normal porcine sera had no effect. Anti-poFcγRII antibody inhibited the enhancement of infection when cells were infected in the presence of anti-PRRSV antibody, but not when cells were infected in the absence of antibody. These results indicate that enhancement of infection in these cells by anti-PRRSV virus antibody is FcγRII-mediated. Identification of the inhibitory FcγR mediating ADE infection should expand our understanding of the mechanisms of pathogenesis for a broad range of infectious diseases and may open many approaches for improvements to the treatment and prevention of such diseases.     

Antiviral action of carbonyl-conjugated pentaene macrolides

Clear antiviral activity of carbonyl-conjugated pentaene macrolides, such as flavofungin, mycothicin, brunefungin and flavopentin was shown on models with infectious and oncogenic viruses. The antibiotics were active against influenza A and B virus. The effect was most pronounced in the in vitro and in ovo systems. On a model of experimental influenza infection of mice with the lethal outcome, antiinfluenzal activity of flavofungin was comparable to that of remantadin. However, unlike the latter one flavofungin and brunefungin inhibited the growth of influenza B virus. The drugs had a pronounced inhibitory effect on variolavaccine virus and prevented formation of foci of cell neoplastic transformation infected with various strains of Rous sarcoma virus.